Lead Product(s) : SNS812
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Microbio
Deal Size : Inapplicable
Deal Type : Inapplicable
Pan-COVID New Drug - SNS812 Achieves Superiority in Phase 2 Study
Details : SNS812 achieves statistical significance with clinically meaningful endpoints in the Phase 2 trial and is the only therapeutic with a broad-spectrum efficacy in multiple coronavirus variants.
Product Name : SNS812
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : SNS812
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Microbio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Doses First Patient in Phase II Study of Silmitasertib for Pneumonia
Details : CX-4945 (silmitasertib) is a first-in-class small molecule CK2 inhibitor being evaluated for treating community-acquired pneumonia associated with viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that targets the CK2 protein and acts as a CK2 inhibitor. It is being developed for the treatment of community-acquired pneumonia associated with viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways. It is expected to be clinically effective against the community-acquired pneumonia caused by viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Y.S.P. Industries M Sdn Bhd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Enters Exclusive License Agreement with YSP
Details : Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
Product Name : TG-1000
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Y.S.P. Industries M Sdn Bhd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants an...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants an...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China
Details : Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant ...
Product Name : TG-1000
Product Type : Other Small Molecule
Upfront Cash : $2.9 million
March 22, 2023
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : UB-421 is an Fc-aglycosylated, non-T cell depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 (domain 1), and competitively blocks H...
Product Name : UB-421
Product Type : Antibody
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : UB-421,Chidamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Silmitasertib is a first-in-class small molecule drug that targets the CK2 pathway and acts as a CK2-inhibitor. It is safe and well-tolerated in humans. In addition to COVID-19, and is currently under development in several oncology programs in adults an...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable